711.2000 -18.40 (-2.52%)
NSE Feb 27, 2026 15:31 PM
Volume: 114.9K
 

Karvy
Valuation and Risks: We upgrade our revenues by 3.2% / 3.3% for FY21E/FY22E at Rs 52 bn / Rs 56 bn respectively due to upgrade in US, ROW and API business.
Alembic Pharma has lost -24.09% in the last 6 Months
More from Alembic Pharmaceuticals Ltd.
Recommended